RecruitingPhase I/IIFemale onlyEN originalOvarian cancerMetastatic / advanced

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Potwierdzona diagnoza zaawansowanego raka jajnika, raka otrzewnej lub raka jajowodu
  • Wcześniejsze leczenie platynią lub niemożność stosowania platyny
  • Nawrót lub pogorszenie się choroby po ostatnim leczeniu
  • Brak innych skutecznych opcji leczenia
  • Prawidłowa funkcja organów i szpiku kostnego
  • Spodziewana długość życia co najmniej 3 miesiące
  • W przypadku raka macicy: potwierdzony rak macicy, który pogorszył się po immunoterapii i chemioterapii platynowej

✗ Disqualifies

  • Wcześniejsze leczenie immunoterapią (PD-1/PD-L1)
  • Wcześniejsze leczenie lekami kierowanymi na MUC16
  • Niezbadany lub aktywny nowotwór mózgu lub przerzuty do mózgu
  • Poważne problemy z sercem lub nadciśnieniem
  • Więcej niż 4 wcześniejsze linie chemioterapii (w kohortach raka jajnika)

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 22, 2026
Sex
Female only

Therapies / drugs in trial

Locations (52)

University of Alabama_6th Ave

Birmingham, United States

Massachusetts General Hospital

Boston, United States

Dana Farber / Harvard Cancer Center

Boston, United States

Mayo Clinic - Rochester

Rochester, United States

Roswell Park Cancer Institute

Buffalo, United States

Columbia University Medical Center

New York, United States

Memorial Sloan Kettering Cancer Center

New York, United States

The Ohio State University Wexner Medical Center

Columbus, United States

Stephenson Cancer Center

Oklahoma City, United States

Sarah Cannon Research Institute

Nashville, United States

Virginia Commonwealth University

Richmond, United States

Prince of Wales Hospital

Randwick, Australia

Peter MacCallum Cancer Center

Melbourne, Australia

Universitair Ziekenhuis Antwerpen

Edegem, Belgium

Grand Hopital de Charleroi

Charleroi, Belgium

UZLeuven

Leuven, Belgium

Hopital Lyon Sud

Pierre-Bénite, France

Centre Georges Francois Leclerc

Dijon, France

Institut Bergonie

Bordeaux, France

Centre Francois Baclesse (CFB)

Caen, France

Centre Antoine Lacassagne

Nice, France

Institut Gustave Roussy

Villejuif, France

Rambam Health Care Campus

Haifa, Israel

Sharet Institute of Oncology

Jerusalem, Israel

Sheba Medical Center

Tel Litwinsky, Israel

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy

Humanitas S. Pio X

Milan, Italy

Istituto Europeo di Oncologia

Milan, Italy

Instituto Nazionale Tumori- Fondazione Pascale

Naples, Italy

Radboudumc

Nijmegen, Netherlands

Erasmus MC

Rotterdam, Netherlands

University Medical Center Groningen

Groningen, Netherlands

Yonsei University Health System

Seoul, South Korea

Asan Medical Center, Univ. of Ulsan

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Korea University Guro Hospital

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Clinica Universidad de Navarra

Pamplona, Spain

Institut Catala dOncologia Badalona

Badalona, Spain

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Institut Catala d'Oncologia

Barcelona, Spain

Clinica Universidad Navarra (CUN) Madrid

Madrid, Spain

Fundacion Jimenez Diaz

Madrid, Spain

Hospital Universitario San Carlos

Madrid, Spain

Hospital Clinico Universitatio Santiago de Compostela

Santiago de Compostela, Spain

University of Oxford

Oxford, United Kingdom

Royal Marsden Hospital - Sutton

Sutton, United Kingdom

The Royal Marsden NHS Foundation Trust

Sutton, United Kingdom

University College London Hospitals

London, United Kingdom

Guys Hospital

London, United Kingdom

Imperial College Healthcare NHS Trust

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom

Trial contact

Clinical Trials Administrator

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.